Business Context and Reporting Period
Company: SpyGlass Pharma, Inc. (SGP)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: SpyGlass is a late-stage biopharmaceutical company developing the SpyGlass Platform, a drug delivery technology for chronic eye conditions. Its lead product candidate, the BIM-IOL System, is a drug-device combination designed to deliver bimatoprost over three years during routine cataract surgery to treat open-angle glaucoma (OAG) and ocular hypertension (OHT). The company has no approved products and generates no revenue.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(39,869) | $(29,164) |
| Operating Expenses | $41,449 | $27,064 |
| Cash and Cash Equivalents (Dec 31, 2025) | $96,358 | $16,268 |
| Short-Term Investments (Dec 31, 2025) | $11,078 | $0 |
| Total Liquidity (Cash + Investments) | $107,436 | $16,268 |
| Accumulated Deficit | $(104,730) | $(64,861) |
Note: The company completed its Initial Public Offering (IPO) in February 2026, raising approximately $172.5 million in gross proceeds. This event is disclosed as a subsequent event and is not reflected in the December 31, 2025 balance sheet.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $10.7 million (37%) from 2024 to 2025, driven primarily by increased operating expenses.
- Operating Expenses: Total operating expenses rose 53% to $41.4 million.
- R&D Expenses: Increased 46% to $29.2 million due to headcount growth and costs associated with Phase 1/2 and Phase 3 clinical trials.
- G&A Expenses: Increased 73% to $12.3 million, driven by legal and professional services related to the IPO and increased headcount.
- Liquidity Position: Cash and cash equivalents increased significantly from $16.3 million to $96.4 million, bolstered by $127.3 million in gross proceeds from Series C-2 and Series D preferred stock financings during 2025.
- Financing Activities: Net cash provided by financing activities was $124.6 million in 2025, compared to $0.2 million in 2024.
Guidance, Outlook, and Risks
Clinical Development Outlook
- Phase 3 Trials: Two registrational Phase 3 trials for the BIM-IOL System were initiated in July 2025. Enrollment is expected to complete in 2027.
- Regulatory Submission: Pending successful Phase 3 results, the company plans to submit a 505(b)(2) New Drug Application (NDA) to the FDA in 2028.
- Secondary Pipeline: The company is developing the BIM-DRS (Drug Ring System), a non-IOL-based implant, with First-in-Human (FIH) trials planned for 2026.
Liquidity and Capital Resources
Management believes that existing cash, cash equivalents, and short-term investments as of December 31, 2025, combined with net proceeds from the February 2026 IPO, will be sufficient to fund operating expenses and capital expenditure requirements through 2028.
Material Risks and Contingencies
- Internal Controls: The company identified a material weakness in its internal control over financial reporting related to insufficient personnel, lack of risk assessment processes, and lack of segregation of duties. Remediation efforts are underway.
- Legal Proceedings: Glaukos Corporation filed a lawsuit in September 2025 alleging trade secret misappropriation and unfair competition. The company denies the allegations and intends to defend vigorously. A trial is set for October 2026.
- Profitability: The company has incurred recurring losses since inception and expects to continue incurring significant losses for the foreseeable future. It has no products approved for commercial sale.
- Regulatory Risk: There is no guarantee that clinical trials will produce positive results or that the FDA will approve the BIM-IOL System.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $107.4 million cash balance (pre-IPO) plus IPO proceeds to fund operations through 2028, given the capital-intensive nature of Phase 3 trials.
- Internal Control Remediation: Monitor the progress of remediation for the identified material weakness in internal controls over financial reporting.
- Legal Litigation: Track the status of the Glaukos Corporation lawsuit, including the outcome of the trial scheduled for October 2026, as it could impact IP rights and financial resources.
- Clinical Milestones: Confirm enrollment progress in the two Phase 3 trials and the timeline for topline data release (expected 2028).
- Reimbursement Strategy: Assess the feasibility of the proposed reimbursement model (Medicare Part B with a new J-code) and the potential impact of healthcare policy changes.